A Review of Varenicline’s Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Schizophrenia is a severe psychiatric disorder affecting 1% of the world's population. Nicotine addiction is one of the most important health concerns for patients with schizophrenia. An extensive body of evidence points to a high prevalence rate of comorbid nicotine addiction in people with schizophrenia (70-90%), which contributes to significant cardiovascular and cancer risks in this vulnerable population. Therefore, effective smoking cessation strategies could play a major role in preventing significant morbidity and mortality in this population. Two of the most common pharmacological approaches to smoking cessation, bupropion and nicotine replacement therapy (NRT), have been used in psychiatric patients to reduce their smoking. In 2006, varenicline, a partial agonist of α4β2 acetylcholine receptor, was approved for smoking cessation by the FDA. This drug not only has the beneficial effects on withdrawal symptoms, but also reduces craving and rewarding effects of smoking. While varenicline has been shown to be an effective, safe medication for the general population, its efficacy and safety for subjects with schizophrenia is less well characterized. A number of case studies have prompted FDA warnings about the potential exacerbation of psychiatric symptoms. However, other case studies and pilot studies have shown varenicline to be a safe and effective treatment for smoking cessation in subjects with schizophrenia. Varenicline has the potential to reduce smoking in subjects with schizophrenia, however, clinicians should carefully monitor patients receiving varenicline for potential exacerbation of psychiatric symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 3×
“Nausea has been reported as the most common side effect with varenicline [57,59].”
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 3×
“Nausea has been reported as the most common side effect with varenicline [57,59].”
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320
de Leon, J., & Diaz, F. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.010 · Cited by 1,276 · cited 1×
“Smoking cessation rates among patients with schizophrenia are considerably lower than for other psychiatric disorders [10,11].”
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058 · cited 1×
“Several reports find a strong association between smoking and schizophrenia with prevalence rates ranging from 74% [5] to as high as 90% [6–8], as compared to national average of 20% in individuals who do not have a diagnosis of schizophrenia [9].”
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi, S. H., & Folsom, T. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn187 · Cited by 860 · cited 1×
“Schizophrenia is a major debilitating and neurodevelopmental [1] disorder which affects an estimated 1% of the world’s population.”
Self-citationTobacco use and cessation in psychiatric disorders: National Institute of Mental Health report
Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M., Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown, R. A., George, T. P., Williams, J., et al. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802443569 · Cited by 735
Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats
Imperato, A., Mulas, A., & Di Chiara, G. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90629-1 · Cited by 693
Schizophrenia, sensory gating, and nicotinic receptors
Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., et al. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033320 · Cited by 690
Cited by
Anthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., Ascher, J., Russ, C., Krishen, A., & Evins, A. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30272-0 · Cited by 1,177
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
“Accumulating evidence shows that varenicline is also effective and safe in schizophrenic patients [105-110].”
BackgroundRoberts, E., Eden Evins, A., McNeill, A., & Robson, D. (2016) · Addiction · doi:10.1111/add.13236 · Cited by 119
“Such an analysis is particularly pertinent, as these treatments appear to be underutilized in smokers with SMI, and there remain perceived concerns about the tolerability of their use, particularly surrounding concerns of alteration in mental state and suicidal ideation [23,29].”
BackgroundEfficacy and safety of varenicline for smoking cessation in schizophrenia: a meta-analysis.
Ahmed, S., Virani, S., Kotapati, V. P., Bachu, R., Adnan, M., Khan, A. M., Zubair, A., Begum, G., Kumar, J., Qureshi, M., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00428 · Cited by 20
“There is a strong association between schizophrenia and smoking behaviors, with prevalence rates ranging from 70 to 90%; as a comparison, smoking rates of the general population in the United States stands at∼30% (1, 2).”
Background
Metadata
- Authors
- Yousefi, M. K., & . Folsom, T. D.
- Venue
- Journal of Addiction Research & Therapy
- Publisher
- OMICS Publishing Group
- Published
- 2012
- Volume
- 01
- Issue
- S4
- ISSN
- 2155-6105 (ISSN-L)
- OpenAlex
- W2107691380
- Cited by
- 25
- References
- 23
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of Varenicline’s Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. https://app.cochat.ai/papers/10.4172/2155-6105.s4-001
- The paper
- Yousefi, M. K., & . Folsom, T. D. (2012). A Review of Varenicline’s Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.s4-001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.